

Supplemental File 1:

Table 1. Full version of Table 2 showing comprehensive list of model modifications

No.	Model Modification	Improvement on Yeast 7.11	Reference
Addition of Reactions to Yeast 7.11	1 Addition of alpha-keto isovalerate transport 3-methyl 2-oxobutanoate [m] ⇌ 3-methyl 2-oxobutanoate [c]	<ul style="list-style-type: none"> • <i>BAT1</i> reconciled from ESG to GG • <i>BAT1-BAT2</i> reconciled from SL2ES to SL2SL2. 	[1] [2]
	2 Addition of pretyrosine formation prephenate [c] + L-glutamate [c] ⇌ 2-oxoglutarate [c] + pretyrosine [c] GPR: <i>YGL202W</i> and <i>YHR137W</i>	Addition of prephenate aminotransferase in the pretyrosine pathway and also retains <i>YGL202W</i> and <i>YHR137W</i> as GG.	[3] [4] [5]
	3 Addition of pretyrosine dehydratase pretyrosine [c] ⇌ CO ₂ [c] + H ₂ O [c] + L-phenylalanine [c] GPR: <i>YNL316C</i>	Addition of pretyrosine dehydratase in the pretyrosine pathway also retaining <i>YNL316C</i> as GG.	[6]
	4 Addition of tyrosine degradation pathway 3-(4-hydroxyphenyl) pyruvate [c] → CO ₂ [c] + 3-(4-hydroxyphenyl) acetaldehyde [c] GPR: unknown EC 4.1.1.80	Addition of (4-hydroxyphenyl) pyruvate decarboxylase in the tyrosine degradation pathway. The ORF for the gene is unknown but this pathway is non-essential for viability hence adds to GG.	[7] [8]
	5 Addition of tyrosine degradation pathway 3-(4-hydroxyphenyl) acetaldehyde [c] + NADH [c] → NAD ⁺ [c] + tyrosol [c] GPR: unknown EC 1.1.1.1	Addition of reduction reaction to form alcohol from aldehyde in tyrosine degradation pathway is similarly non-essential for viability and so GG.	[7] [8]
	6 Mitochondrial acetyl-transferase activity of glycine CoA [c] + L-2 amino 3-oxobutanoate [c] ⇌ acetyl-CoA [m] + L-glycine [m] GPR: <i>YDL040C</i> or <i>YGR147C</i> or <i>YHR013C</i>	<ul style="list-style-type: none"> • Correctly adds <i>NAT1</i>, <i>NAT2</i> and <i>ARD1</i> as GG cases. 	[9] [10]
	7 GPR modification for reaction r_0195 Old GPR: ((<i>YBR126C</i> and <i>YDR074W</i> and <i>YMR261C</i>) or (<i>YML100W</i> and <i>YBR126C</i> and <i>YDR074W</i>)) New GPR: ((<i>YBR126C</i> and <i>YDR074W</i> and <i>YMR261C</i> and <i>YML100W</i>) or <i>YBR126C</i>)	<ul style="list-style-type: none"> • <i>TPS1</i> gene is only essential in glucose media whereas both <i>TPS1</i> and <i>TPS2</i> genes are essential in galactose media reflected in old GPR • <i>TPS2</i> gene is restored as a GG from an ESG 	[11] [12] [13]
	8 GPR modification for reaction r_1051 Old GPR: ((<i>YBR126C</i> and <i>YDR074W</i> and <i>YMR261C</i>) or (<i>YML100W</i> and <i>YBR126C</i> and <i>YDR074W</i>)) New GPR: ((<i>YBR126C</i> and <i>YDR074W</i> and <i>YMR261C</i> and <i>YML100W</i>) or <i>YBR126C</i>)	<ul style="list-style-type: none"> • <i>TPS1</i> gene is only essential in glucose media whereas both <i>TPS1</i> and <i>TPS2</i> genes are essential in galactose media reflected in old GPR • <i>TPS2</i> gene is restored as a GG from an ESG 	[11] [12] [13]
	9 GPR modification for reaction r_0995 Old GPR: <i>YDR023W</i> or <i>YHR011W</i>	<ul style="list-style-type: none"> • <i>SES1</i> gene is corrected from GES to ESES • <i>SES1-DIA1</i> is corrected from SL2ES and SL2G cases to 	[14] [15]

New GPR: *YDR023W* or (*YDR023W* and *YHR011W*)

ESES and GG cases respectively.

- | | | | |
|----|---|--|--------------|
| 10 | <p>GPR modification for reaction r_0916</p> <p>Old GPR: ((<i>YHL011C</i> and <i>YKL181W</i>) or (<i>YOL061W</i> and <i>YBL068W</i>) or (<i>YOL061W</i> and <i>YER099C</i>))</p> <p>New GPR: ((<i>YKL181W</i> and <i>YER099C</i>) or (<i>YKL181W</i> and <i>YHL011C</i>) or (<i>YKL181W</i> and <i>YBL068W</i>) or (<i>YER099C</i> and <i>YOL061W</i>) or (<i>YBL068W</i> and <i>YOL068W</i>))</p> | <ul style="list-style-type: none"> • The new GPR suggests 4 new probable lethal triplet mutants namely: $\Delta prs1\Delta prs2\Delta prs4$, $\Delta prs1\Delta prs2\Delta prs5$, $\Delta prs1\Delta prs3\Delta prs5$, $\Delta prs2\Delta prs3\Delta prs4$ and $\Delta prs1\Delta prs4\Delta prs5$ | [16] |
| 11 | <p>GPR modification for reaction r_1178</p> <p>Old GPR: <i>YMR319C</i></p> <p>New GPR: <i>YMR319C</i> or <i>YMR058W</i></p> | <ul style="list-style-type: none"> • Iron (II) transporter across plasma membrane has 2 different genes encoding under low-affinity and high-affinity conditions • <i>FET4</i> gene is reconciled from ESG to GG • <i>FET3</i> gene is added to the model as a non-essential gene • <i>FET3-FET4</i> <i>in vivo</i> lethal gene pair is correctly predicted by model now | [17] |
| 12 | <p>GPR modification for reaction r_0250</p> <p>Old GPR: ((<i>YJR019C</i> and <i>YOR303W</i>) or <i>YJL130C</i>)</p> <p>New GPR: <i>YJR019C</i> and <i>YOR303W</i> and <i>YJL130C</i></p> | <ul style="list-style-type: none"> • SL2ES <i>CPA2-URA2</i> is resolved correctly to 2 ESES cases <i>CPA2</i> and <i>URA2</i> • SL2ES <i>CPA1-URA2</i> is resolved correctly to one more ESES case <i>CPA1</i> • At the same time it resolves 3 GES to ESES cases for the genes <i>CPA1</i>, <i>CPA2</i>, <i>URA2</i> | [18]
[19] |
| 13 | <p>GPR modification for reactions r_0886 and r_0887 along with suppression of PIT2m reaction (r_1245) due to Crabtree effect</p> <p>Old GPR: <i>YMR205C</i> and <i>YGR240C</i></p> <p>New GPR: <i>YMR205C</i> or (<i>YGR240C</i> and <i>YMR205C</i>)</p> | <ul style="list-style-type: none"> • Resolves <i>YDR050C-YMR205C</i> SL2ES case to ESES • Resolves <i>YDR050C-YGR240C</i> SL2G cases to GG • Resolves <i>YMR205C-YGR240C</i> GSL2 to SL2SL2 • Resolves <i>tpi1-fba1</i> SL2ES to ESES cases • Resolves <i>tpi1</i> from GES to ESES • Resolves <i>fba1</i> from GES to ESES | [20]
[21] |
| 14 | <p>GPR modification of reaction r_2116</p> <p>Old GPR: <i>ALD2</i></p> <p>New GPR: <i>ALD2</i> or <i>ALD5</i> or <i>ALD4</i></p> | <ul style="list-style-type: none"> • Resolves <i>ALD2</i> from SL2G to GG | [22] |
| 15 | <p>GPR modification of reaction r_0020</p> <p>Old GPR: <i>YDR035W</i></p> <p>New GPR: <i>YDR035W</i> or <i>YBR249C</i></p> | <ul style="list-style-type: none"> • Resolves <i>MAE1</i> from SL2G to GG | [23] |
| 17 | <p>GPR modification of reaction r_0116</p> <p>Old GPR: <i>PHO11</i> or <i>PHO5</i></p> <p>New GPR: <i>PHO11</i> or <i>PHO12</i> or <i>PHO3</i> or <i>PHO5</i></p> | <ul style="list-style-type: none"> • Adds genes <i>PHO5</i> and <i>PHO12</i> to the model and correctly identified as GG | [24] |

	18	GPR modification of reaction r_1237 Old GPR: <i>YOR130C</i> New GPR: <i>YOR130C</i> or <i>BAC1</i>	<ul style="list-style-type: none"> • Resolves <i>ORT1</i> from ESG to GG • Prediction of SL2U for <i>ORT1-BAC1</i> 	[25]
	19	GPR modification for reaction r_0005 Old GPR: <i>YGR032W</i> or <i>YLR342W</i> New GPR: (<i>YGR032W</i> or <i>YLR342W</i>) and (<i>YCR034W</i> or <i>YLR372W</i>)	<ul style="list-style-type: none"> • Identifies <i>YCR034W-YLR372W</i> as SL2SL2 from GSL2 cases 	[26]
	20	GPR modification for reaction r_0888 Old GPR: <i>YMR105C</i> or <i>YKL127W</i> New GPR: (<i>YMR105C</i> or <i>YKL127W</i>) and (<i>YMR105C</i> or <i>YKL127W</i> or <i>YMR278W</i>)	<ul style="list-style-type: none"> • Retains <i>PGM1-PGM2</i> SL2SL2 case and adds <i>PGM3</i> as a GG in the model. 	[27]
Removal of reactions	21	Remove orphan reaction r_2031 It was initially suggested in <i>iAZ900</i>	Reconciles GSL2 of <i>fur1-ura3</i> case to SL2SL2	
	22	Remove reaction r_1682	Removes duplicate reaction, which is a lumped version of reactions r_0986, r_0243, r_0242, r_0244.	[28]
	23	Remove reaction r_0461	<ul style="list-style-type: none"> • Should not be present in <i>S. cerevisiae</i>, seen in <i>M. mazei</i> and also confirmed in UniProt. 	[29]
Add genes to orphan reactions	24	Add an <i>E. coli</i> like <i>ubiC</i> gene for reaction r_1685. We call it here <i>Y-ubiC</i> gene. Chorismate [c] ⇌ 4-hydroxybenzoate [c] + pyruvate [c] GPR: unknown	<ul style="list-style-type: none"> • The ORF is unknown but the gene has been identified as GG. • Adds GPR to an orphan reaction 	[30] [31] [32]
	25	Add genes for reaction r_0026 4-methyl thio-2-oxobutanoate [c] + L-glutamate [c] ⇌ 2-oxoglutarate [c] + L-methionine [c]	<ul style="list-style-type: none"> • Adds GPR: <i>YHR208W</i> or <i>YJR148W</i> or <i>YGL202W</i> or <i>YHR137W</i> where all 4 genes are correctly identified as GG 	[33]
	26	Add genes for reaction r_0043 3-hexaprenyl-4-hydroxybenzoic acid [c] + 0.5 oxygen [c] ⇌ 3-hexaprenyl-4,5 dihydroxybenzoate [c]	Adds GPR: <i>YPL252C</i> or <i>YDR376W</i> Both the genes are correctly identified as GG	[34]
	27	Add genes for reaction r_0044 3-hexaprenyl-4-hydroxy-5-methoxybenzoic acid [m] + H ⁺ [m] ⇌ 2-hexaprenyl-6-methoxyphenol [m] + CO ₂ [m]	Adds GPR: <i>YDR538W</i> and <i>YDR539W</i> Both the genes are correctly identified as GG	[35]

28	Add genes for reaction r_0086 S-methyl-5-thio-D-ribulose 1-phosphate [c] ⇌ 5-methyl sulfanyl-2,3-dioxopentyl phosphate [c] + H ₂ O [c]	Adds GPR: <i>YJR024C</i> It is correctly identified as GG	[36]
29	Add genes for reaction r_0087 S-methyl-5-thio alpha ribose 1-phosphate [c] ⇌ S-methyl-5-thio-D-ribulose 1-phosphate [c]	Adds GPR: <i>YPR118W</i> It is correctly identified as GG	[33]
30	Add genes for reaction r_0094 L-alanine [c] + pimeloyl-CoA [c] ⇌ 8-amino-7 oxononanoate [c] + CO ₂ [c] + CoA [c] + 4H ⁺ [c]	<ul style="list-style-type: none"> Adds GPR: <i>YAR069W-A</i> or <i>YHR214W-F</i> Adds genes <i>BIO6</i> and <i>BIO8</i> putative genes to the model and both are correctly predicted as GG. 	[37]
31	Add genes for reaction r_0475 H ₂ O [c] + L-glutamine [c] ⇌ ammonium [c] + L-glutamate [c]	<ul style="list-style-type: none"> Adds GPR: <i>YMR096W</i> or (<i>YMR095C</i> and <i>YMR096W</i>) Adds genes <i>SNZ1</i> and <i>SNO1</i> to the model Correctly identifies <i>SNZ1</i> and <i>SNO1</i> genes as GG 	[38]
32	Add genes for reaction r_0992 Acetyl-CoA [c] + L-serine [c] ⇌ CoA [c] + O-acetyl-L-serine [c]	<ul style="list-style-type: none"> Adds GPR: (<i>YDL040C</i> and <i>YGR147C</i> and <i>YHR013C</i>) or (<i>YDL040C</i> and <i>YGR147C</i>) 	[39]
33	Add genes for reaction r_1623 5-formyltetrahydro folate [m] + ATP [m] ⇌ 5,10 methenyl-THF [m] + ADP [m] + P _i [m]	Adds GPR: <i>YER183C</i>	[40]
34	Add genes for reaction r_1624 5-formyltetrahydro folate [c] + ATP [c] + H ₂ O [c] ⇌ 10-formyl THF [c] + ADP [c] + P _i [c] + H ⁺ [c]	Adds GPR: <i>YER183C</i>	[40]
35	Adds GPR to reaction r_1603 GPR: <i>ADE5,7</i>	Correctly identified to be a GG	[41]
36	Adds GPR to reaction r_0696 GPR: <i>YOL151W (GRE2)</i>	Correctly identified to be a GG	[42]
37	Adds GPR to reaction r_1739 GPR: <i>PAA1</i>	Correctly identified to be a GG	[43]
38	Adds GPR to reaction r_1790 GPR: <i>YDL045C</i>	Correctly identified to be a GG	[44]

Table 2. Summary of results showing improvement of ES and SL prediction of *iSce926* over Yeast 7.11

Description	<i>iSce926</i>	Yeast 7.11	Comments
Correct prediction of <i>in vivo</i> essential genes = ESES	92	72	<i>iSce926</i> shows 27.7% better performance than Yeast 7.11
Correct prediction of <i>in vivo</i> synthetic lethal genes = SL2SL2+SL3SL3	17	23	<i>iSce926</i> shows 35.2% better performance than Yeast 7.11
Reduction of erroneous prediction of <i>in vivo</i> non-essential genes = ESG	30	14	<i>iSce926</i> shows 53.3% reduction in erroneous prediction than Yeast 7.11
Suggested lethal knockout experiments (pairs and triples) = SL2U+SL3U	15	27	<i>iSce926</i> shows 80% increase in suggested gene deletion experiments than Yeast 7.11
Selectivity= ESES/(ESES+GES)	0.347	0.288	<i>iSce926</i> shows 20.4% increase in selectivity than Yeast 7.11
Specificity= GG/(GG+ESG)	0.951	0.977	<i>iSce926</i> shows 2.7% increase in specificity than Yeast 7.11

Table 3. Full version of Table 6 showing agreement, disagreement with *in vivo* data and model modifications in CHO 1.2

		Gene name	Comments	Modifications	Reference
Single Gene Deletion	Match between <i>in vivo</i> and <i>in silico</i>	<i>acsL3</i>	$\Delta acsL3$ strain has an impaired Liver-X Receptor/ Retinoid-X Receptor signalling pathway in CHO cells. CHO-K1 cell lines show mutant strains have impaired lipid biosynthesis. <i>In silico</i> mutant strain shows sphingomyelin auxotrophy. However, <i>in vivo</i> lethality endorses <i>in silico</i> predictions.		[45] [46] [45]
		<i>ggypS1</i>	$\Delta ggypS1$ strain has an impaired carotenoid biosynthesis <i>in vivo</i> . Similarly, mouse and human $\Delta ggypS1$ cell lines were also found to be inviable since it is an important G-protein precursor. <i>In silico</i> mutant strain is cholesterol auxotroph, hence inviable. Thus <i>in vivo</i> result matches <i>in silico</i> predictions.		[47] [48] [47]
		<i>fasN</i>	<i>fasN</i> gene is shown to be highly conserved in mammalian systems. $\Delta fasN$ strain has been shown to shut off the lipid biosynthesis and hence renders the strain inviable in mouse. It can be extrapolated as a compliance of <i>in vivo</i> and <i>in silico</i> results.		[49] [50]
		<i>hmgCr</i>	<i>hmgCr</i> gene shows more than 80% homology in CHO cells with humans and mouse counterparts. <i>In vivo</i> mouse and <i>in silico</i> CHO $\Delta hmgCr$ strains are cholesterol auxotrophs and thus affirm conformation.		[51]
	Mismatch between <i>in vivo</i> and <i>in silico</i>	<i>dhfr</i>	Deletion of <i>dhfr</i> prevents biomass precursor sphingomyelin formation <i>in silico</i> , However, this deletion is not lethal <i>in vivo</i> in CHO-K1 cell lines.		[46]
		<i>gys1</i>	$\Delta gys1$ <i>in silico</i> mutant strain is glycogen auxotroph. <i>in vivo</i> studies show <i>gys1</i> - mutant is viable and forms SL2 with <i>gys2</i> .	GPR modified from: (<i>gys1</i> and <i>gys2</i>) to (<i>gys1</i> or <i>gys2</i>) <i>gys1</i> and <i>gys2</i> reconciled from ESG to GG <i>gys1-gys2</i> reconciles from ESG to SL2SL2	[52] [53] [54]
		<i>acsL1</i> , <i>acsL3</i> , <i>acsL4</i>	$\Delta acsL4$ <i>in silico</i> mutant is sphingomyelin auxotroph. However, <i>in vivo</i> data for mouse reveals that <i>acsL4</i> deletion is viable.	r_0147 and r_0148 GPR was modified from <i>acsL4</i> to (<i>acsL1</i> or <i>acsL3</i> or <i>acsL4</i>) r_0142 GPR was modified from <i>acsL1</i> to (<i>acsL1</i> or <i>acsL3</i> or <i>acsL4</i>) r_0146 GPR was modified from <i>acsL3</i> to (<i>acsL1</i> or <i>acsL3</i> or <i>acsL4</i>) <i>acsL1</i> , <i>acsL3</i> and <i>acsL4</i> were fixed from ESG to GG	[55]
		<i>afmld</i>	$\Delta afmld$ <i>in silico</i> mutant is sphingomyelin auxotroph. However, <i>in vivo</i> data for mouse reveals that <i>afmld</i> deletion is viable.		[56]

Single gene deletion	Suggestion for CHO-K1 single gene deletion			
	<i>arg1</i>	$\Delta arg1$ mutant <i>in silico</i> is spermidine and putrescine auxotroph. Mouse knockout experiments show that it is <i>in vivo</i> essential. But due to lack of gene homology information, this serves as an important suggestion for an experimentalist to perform in CHO-K1 cell line.	[57]	
	<i>mthFr</i>	$\Delta mthFr$ mutant <i>in silico</i> is 5-methyl tetrahydrofolate auxotroph and hence inviable. Mouse knockout experiments show that it is <i>in vivo</i> essential. Unavailability of homology information makes it an important suggestion for CHO-K1 single gene deletion candidate.	[58]	
	<i>qprT</i>	$\Delta qprT$ mutant <i>in silico</i> causes auxotrophy of cofactors NAD ⁺ , NADH, NADP ⁺ and NADPH. No experimental evidence of knockout data exists in CHO-K1 cell line. This serves as a potential non-intuitive essential gene.	NA ¹	
	<i>ugp2</i>	$\Delta ugp2$ mutant <i>in silico</i> causes glycogen auxotrophy. No experimental evidence of CHO-K1 knockout data for <i>ugp2</i> exists. This makes it an important suggestion for single gene knockout studies.	NA	
Double gene deletion	Mismatches with experimental evidence			
	<i>pgm1-pgm2</i>	$\Delta pgm1\Delta pgm2$ double mutant is lethal <i>in silico</i> causing glycogen auxotrophy. However, single gene mouse deletion shows $\Delta pgm2$ strain is inviable and there is more than 80% homology in mouse and CHO <i>pgm2</i> .	GPR modification from <i>pgm1</i> or <i>pgm2</i> to <i>pgm2</i> or (<i>pgm1</i> and <i>pgm2</i>). <i>pgm2</i> is fixed from GES to ESES SL2ES case is fixed to ESES	[59]
	<i>pcyT1a-pcyT1b</i>	$\Delta pcyT1a\Delta pcyT1b$ double mutant causes phosphatidylcholine and sphingomyelin auxotrophy <i>in silico</i> . However, <i>in vivo</i> studies reveal that <i>pcyT1a</i> deletion alone is seen to be lethal in mouse.	Changing GPR for phosphatate cytidyltransferase reaction (r_1023) from <i>pcyT1a</i> or <i>pcyT1b</i> to <i>pcyT1a</i> or (<i>pcyT1a</i> and <i>pcyT1b</i>) resolves SL2ES to ESES and GES to ESES with respect to <i>pcyT1a</i> .	[60]
	<i>chkA-chkB</i>	$\Delta chkA$ mouse strains have been shown to be embryonic lethal. However $\Delta chkB$ deletions have been non-lethal.	Changing GPR for choline-kinase reactions r_0359 and r_0360 from <i>chkA</i> or <i>chkB</i> to <i>chkA</i> or (<i>chkA</i> and <i>chkB</i>) resolved SL2ES to ESES and GES to ESES with respect to <i>chkA</i>	[61]
Suggested CHO-K1 experiments	<i>slc14a1-slc14a2</i>	$\Delta slc14a1\Delta slc14a2$ double mutant has been shown to be spermidine and putrescine auxotroph. In a mouse <i>in silico</i> reconstruction ² this has been shown to be lethal pair as well. But there are no experimental evidence so it goes as a suggestion.		NA
	<i>dhcR24-choL4</i>	$\Delta dhcR24\Delta choL4$ double mutant is cholesterol auxotroph in both CHO 1.2 and mouse <i>in silico</i> models. However no experimental single or double deletion data exists.		NA

Suggested CHO-K1 experiments	<i>ptdSs1-ptdSs2</i>	<i>ΔptdSs1ΔptdSs2</i> is incapable of <i>in silico</i> production of phosphatidylserine and phosphatidylethanolamine. The mouse GSM also confirms this <i>in silico</i> lethal pair. However no experimental single or double deletion data exists in either CHO-K1 or mouse.	NA
	<i>gusB-impA2</i>	<i>ΔgusBΔimpA2</i> is incapable of <i>in silico</i> production of 1-phosphatidyl-D-myoinositol. The mouse GSM also confirms this <i>in silico</i> lethal pair. However no experimental single or double deletion data exists in either CHO-K1 or mouse.	NA
Higher order gene deletions	Suggested CHO-K1 experiments		
	<i>dhoDh-fh1-cytB</i>	<i>ΔdhoDhΔfh1ΔcytB</i> triple mutants are incapable of Sphingomyelin production <i>in silico</i> . Neither <i>in silico</i> higher gene deletion information was available from the mouse model nor do we have any mouse or CHO <i>in vivo</i> triple knockout information.	NA
	<i>ggh-pipOx-slc19a1</i>	<i>ΔgghΔpipOxΔslc19a1</i> triple mutants are incapable of 5 methyl tetrahydrofolate production <i>in silico</i> . Neither <i>in silico</i> higher gene deletion information was available from the mouse model nor do we have any mouse or CHO <i>in vivo</i> triple knockout information.	NA
	<i>cox(N)-dhoDh-sdhD</i>	<i>Δcox(N)ΔdhoDhΔsdhD</i> triple mutants are incapable of Sphingomyelin production <i>in silico</i> . Neither <i>in silico</i> higher gene deletion information was available from the mouse model nor do we have any mouse or CHO <i>in vivo</i> triple knockout information. N belongs to {1, 2, 3, 5a, 5b, 6a1, 6a2, 6b1, 6b2, 6c, 7a1, 7a2, 7a2l, 7b, 7c, 8a, 8b} This particular example points to 18 <i>in silico</i> lethal triplets, but we have explained them in results as a single case.	NA
	<i>nanS-npl-st8Sia1-st8Sia5</i>	<i>ΔnanSΔnplΔst8Sia1Δst8Sia5</i> quadruple mutants are incapable of N-acetylneuraminate production <i>in silico</i> . Neither <i>in silico</i> higher gene deletion information was available from the mouse model nor do we have any mouse or CHO <i>in vivo</i> quadruple knockout information.	NA
	<i>ak1-ak2-ak3L1-cmpK1</i>	<i>Δak1Δak2Δak3L1ΔcmpK1</i> quadruple mutants are incapable of phosphatidylglycerol, phosphatidylserine, phosphatidylethanolamine, phosphatidylcholine, cardiolipin, 1-phosphatidyl-D-myoinositol production <i>in silico</i> . Neither <i>in silico</i> higher gene deletion information was available from the mouse model nor do we have any mouse or CHO <i>in vivo</i> quadruple knockout information.	NA

1. Baudin, A.; Ozier-Kalogeropoulos, O.; Denouel, A.; Lacroute, F.; Cullin, C. A simple and efficient method for direct gene deletion in *saccharomyces cerevisiae*. *Nucleic acids research* **1993**, *21*, 3329-3330.
2. Harrison, R.; Papp, B.; Pal, C.; Oliver, S.G.; Delneri, D. Plasticity of genetic interactions in metabolic networks of yeast. *Proceedings of the National Academy of Sciences of the United States of America* **2007**, *104*, 2307-2312.
3. Kradolfer, P.; Niederberger, P.; Hutter, R. Tryptophan degradation in *saccharomyces cerevisiae*: Characterization of two aromatic aminotransferases. *Archives of microbiology* **1982**, *133*, 242-248.
4. Urrestarazu, A.; Vissers, S.; Iraqui, I.; Grenson, M. Phenylalanine- and tyrosine-auxotrophic mutants of *saccharomyces cerevisiae* impaired in transamination. *Molecular & general genetics : MGG* **1998**, *257*, 230-237.
5. Iraqui, I.; Vissers, S.; Cartiaux, M.; Urrestarazu, A. Characterisation of *saccharomyces cerevisiae* *aro8* and *aro9* genes encoding aromatic aminotransferases i and ii reveals a new aminotransferase subfamily. *Molecular & general genetics : MGG* **1998**, *257*, 238-248.
6. Maftahi, M.; Nicaud, J.M.; Levesque, H.; Gaillardin, C. Sequencing analysis of a 24.7 kb fragment of yeast chromosome xiv identifies six known genes, a new member of the hexose transporter family and ten new open reading frames. *Yeast* **1995**, *11*, 1077-1085.
7. Sentheshanuganathan, S. The mechanism of the formation of higher alcohols from amino acids by *saccharomyces cerevisiae*. *The Biochemical journal* **1960**, *74*, 568-576.
8. Dickinson, J.R. Pathways of leucine and valine catabolism in yeast. *Methods Enzymol* **2000**, *324*, 80-92.
9. Gollub, E.G.; Liu, K.P.; Dayan, J.; Adlersberg, M.; Sprinson, D.B. Yeast mutants deficient in heme biosynthesis and a heme mutant additionally blocked in cyclization of 2,3-oxidosqualene. *The Journal of biological chemistry* **1977**, *252*, 2846-2854.
10. Oh-hama, T. Evolutionary consideration on 5-aminolevulinate synthase in nature. *Origins of life and evolution of the biosphere : the journal of the International Society for the Study of the Origin of Life* **1997**, *27*, 405-412.
11. De Silva-Udawatta, M.N.; Cannon, J.F. Roles of trehalose phosphate synthase in yeast glycogen metabolism and sporulation. *Molecular microbiology* **2001**, *40*, 1345-1356.
12. de Lichtenberg, U.; Jensen, L.J.; Brunak, S.; Bork, P. Dynamic complex formation during the yeast cell cycle. *Science* **2005**, *307*, 724-727.
13. Bell, W.; Sun, W.; Hohmann, S.; Wera, S.; Reinders, A.; De Virgilio, C.; Wiemken, A.; Thevelein, J.M. Composition and functional analysis of the *saccharomyces cerevisiae* trehalose synthase complex. *The Journal of biological chemistry* **1998**, *273*, 33311-33319.
14. Barros, M.H.; Nobrega, F.G. Yah1 of *saccharomyces cerevisiae*: A new essential gene that codes for a protein homologous to human adrenodoxin. *Gene* **1999**, *233*, 197-203.
15. Barros, M.H.; Carlson, C.G.; Glerum, D.M.; Tzagoloff, A. Involvement of mitochondrial ferredoxin and *cox15p* in hydroxylation of heme o. *Febs Lett* **2001**, *492*, 133-138.
16. Hove-Jensen, B. Heterooligomeric phosphoribosyl diphosphate synthase of *saccharomyces cerevisiae*: Combinatorial expression of the five *prs* genes in *escherichia coli*. *The Journal of biological chemistry* **2004**, *279*, 40345-40350.

17. Berthelet, S.; Usher, J.; Shulist, K.; Hamza, A.; Maltez, N.; Johnston, A.; Fong, Y.; Harris, L.J.; Baetz, K. Functional genomics analysis of the *saccharomyces cerevisiae* iron responsive transcription factor *aft1* reveals iron-independent functions. *Genetics* **2010**, *185*, 1111-1128.
18. Lim, A.L.; Powers-Lee, S.G. Requirement for the carboxyl-terminal domain of *saccharomyces cerevisiae* carbamoyl-phosphate synthetase. *The Journal of biological chemistry* **1996**, *271*, 11400-11409.
19. Inglis, D.O.; Arnaud, M.B.; Binkley, J.; Shah, P.; Skrzypek, M.S.; Wymore, F.; Binkley, G.; Miyasato, S.R.; Simison, M.; Sherlock, G. The candida genome database incorporates multiple candida species: Multispecies search and analysis tools with curated gene and protein information for candida albicans and candida glabrata. *Nucleic acids research* **2012**, *40*, D667-674.
20. Diaz-Ruiz, R.; Averet, N.; Araiza, D.; Pinson, B.; Uribe-Carvajal, S.; Devin, A.; Rigoulet, M. Mitochondrial oxidative phosphorylation is regulated by fructose 1,6-bisphosphate. A possible role in crabtree effect induction? *The Journal of biological chemistry* **2008**, *283*, 26948-26955.
21. Guaragnella, N.; Zdravlevic, M.; Antonacci, L.; Passarella, S.; Marra, E.; Giannattasio, S. The role of mitochondria in yeast programmed cell death. *Frontiers in oncology* **2012**, *2*, 70.
22. Navarro-Avino, J.P.; Prasad, R.; Miralles, V.J.; Benito, R.M.; Serrano, R. A proposal for nomenclature of aldehyde dehydrogenases in *saccharomyces cerevisiae* and characterization of the stress-inducible *ald2* and *ald3* genes. *Yeast* **1999**, *15*, 829-842.
23. Tkach, J.M.; Yimit, A.; Lee, A.Y.; Riffle, M.; Costanzo, M.; Jaschob, D.; Hendry, J.A.; Ou, J.; Moffat, J.; Boone, C., *et al.* Dissecting DNA damage response pathways by analysing protein localization and abundance changes during DNA replication stress. *Nature cell biology* **2012**, *14*, 966-976.
24. Shnyreva, M.G.; Petrova, E.V.; Egorov, S.N.; Hinnen, A. Biochemical properties and excretion behavior of repressible acid phosphatases with altered subunit composition. *Microbiological research* **1996**, *151*, 291-300.
25. Zomorodi, A.R.; Maranas, C.D. Improving the *imm904* s. *Cerevisiae* metabolic model using essentiality and synthetic lethality data. *BMC systems biology* **2010**, *4*, 178.
26. Oh, C.S.; Toke, D.A.; Mandala, S.; Martin, C.E. *Elo2* and *elo3*, homologues of the *saccharomyces cerevisiae* *elo1* gene, function in fatty acid elongation and are required for sphingolipid formation. *The Journal of biological chemistry* **1997**, *272*, 17376-17384.
27. Walther, T.; Baylac, A.; Alkim, C.; Vax, A.; Cordier, H.; Francois, J.M. The *pgm3* gene encodes the major phosphoribomutase in the yeast *saccharomyces cerevisiae*. *Febs Lett* **2012**, *586*, 4114-4118.
28. Herrgard, M.J.; Swainston, N.; Dobson, P.; Dunn, W.B.; Arga, K.Y.; Arvas, M.; Bluthgen, N.; Borger, S.; Costenoble, R.; Heinemann, M., *et al.* A consensus yeast metabolic network reconstruction obtained from a community approach to systems biology. *Nature biotechnology* **2008**, *26*, 1155-1160.
29. Ogawa, T.; Yoshimura, T.; Hemmi, H. Connected cavity structure enables prenyl elongation across the dimer interface in mutated geranyltransferase diphosphate synthase from *methanosarcina mazei*. *Biochemical and biophysical research communications* **2011**, *409*, 333-337.
30. Meganathan, R. Ubiquinone biosynthesis in microorganisms. *FEMS microbiology letters* **2001**, *203*, 131-139.
31. Nichols, B.P.; Green, J.M. Cloning and sequencing of *escherichia coli* *ubiC* and purification of chorismate lyase. *Journal of bacteriology* **1992**, *174*, 5309-5316.
32. Siebert, M.; Severin, K.; Heide, L. Formation of 4-hydroxybenzoate in *escherichia coli*: Characterization of the *ubiC* gene and its encoded enzyme chorismate pyruvate-lyase. *Microbiology* **1994**, *140* (Pt 4), 897-904.
33. Petti, A.A.; Crutchfield, C.A.; Rabinowitz, J.D.; Botstein, D. Survival of starving yeast is correlated with oxidative stress response and nonrespiratory mitochondrial function. *Proceedings of the National Academy of Sciences of the United States of America* **2011**, *108*, E1089-1098.
34. Ozeir, M.; Muhlenhoff, U.; Webert, H.; Lill, R.; Fontecave, M.; Pierrel, F. Coenzyme q biosynthesis: *Coq6* is required for the c5-hydroxylation reaction and substrate analogs rescue *coq6* deficiency. *Chemistry & biology* **2011**, *18*, 1134-1142.
35. Mukai, N.; Masaki, K.; Fujii, T.; Kawamukai, M.; Iefuji, H. *Pad1* and *fdc1* are essential for the decarboxylation of phenylacrylic acids in *saccharomyces cerevisiae*. *Journal of bioscience and bioengineering* **2010**, *109*, 564-569.
36. Pirkov, I.; Norbeck, J.; Gustafsson, L.; Albers, E. A complete inventory of all enzymes in the eukaryotic methionine salvage pathway. *The FEBS journal* **2008**, *275*, 4111-4120.
37. Hall, C.; Dietrich, F.S. The reacquisition of biotin prototrophy in *saccharomyces cerevisiae* involved horizontal gene transfer, gene duplication and gene clustering. *Genetics* **2007**, *177*, 2293-2307.

38. Tobias, S.; Rajic, I.; Vanyi, A. Effect of t-2 toxin on egg production and hatchability in laying hens. *Acta veterinaria Hungarica* **1992**, *40*, 47-54.
39. Gautschi, M.; Just, S.; Mun, A.; Ross, S.; Rucknagel, P.; Dubaquier, Y.; Ehrenhofer-Murray, A.; Rospert, S. The yeast n(alpha)-acetyltransferase nata is quantitatively anchored to the ribosome and interacts with nascent polypeptides. *Molecular and cellular biology* **2003**, *23*, 7403-7414.
40. Holmes, W.B.; Appling, D.R. Cloning and characterization of methenyltetrahydrofolate synthetase from *saccharomyces cerevisiae*. *The Journal of biological chemistry* **2002**, *277*, 20205-20213.
41. Henikoff, S. The *saccharomyces cerevisiae* ade5,7 protein is homologous to overlapping *drosophila melanogaster* gart polypeptides. *Journal of molecular biology* **1986**, *190*, 519-528.
42. Guo, P.C.; Bao, Z.Z.; Ma, X.X.; Xia, Q.; Li, W.F. Structural insights into the cofactor-assisted substrate recognition of yeast methylglyoxal/isovaleraldehyde reductase gre2. *Biochimica et biophysica acta* **2014**, *1844*, 1486-1492.
43. Liu, B.; Sutton, A.; Sternglanz, R. A yeast polyamine acetyltransferase. *The Journal of biological chemistry* **2005**, *280*, 16659-16664.
44. Wu, M.; Repetto, B.; Glerum, D.M.; Tzagoloff, A. Cloning and characterization of fad1, the structural gene for flavin adenine dinucleotide synthetase of *saccharomyces cerevisiae*. *Molecular and cellular biology* **1995**, *15*, 264-271.
45. Poppelreuther, M.; Rudolph, B.; Du, C.; Grossmann, R.; Becker, M.; Thiele, C.; Eehalt, R.; Fullekrug, J. The n-terminal region of acyl-coa synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake. *Journal of lipid research* **2012**, *53*, 888-900.
46. Dong, B.; Kan, C.F.; Singh, A.B.; Liu, J. High-fructose diet downregulates long-chain acyl-coa synthetase 3 expression in liver of hamsters via impairing lxr/rxr signaling pathway. *Journal of lipid research* **2013**, *54*, 1241-1254.
47. Ruppel, N.J.; Kropp, K.N.; Davis, P.A.; Martin, A.E.; Luesse, D.R.; Hangarter, R.P. Mutations in geranylgeranyl diphosphate synthase 1 affect chloroplast development in *arabidopsis thaliana* (brassicaceae). *American journal of botany* **2013**, *100*, 2074-2084.
48. Kainou, T.; Kawamura, K.; Tanaka, K.; Matsuda, H.; Kawamukai, M. Identification of the ggps1 genes encoding geranylgeranyl diphosphate synthases from mouse and human. *Biochimica et biophysica acta* **1999**, *1437*, 333-340.
49. Chirala, S.S.; Chang, H.; Matzuk, M.; Abu-Elheiga, L.; Mao, J.; Mahon, K.; Finegold, M.; Wakil, S.J. Fatty acid synthesis is essential in embryonic development: Fatty acid synthase null mutants and most of the heterozygotes die in utero. *Proceedings of the National Academy of Sciences of the United States of America* **2003**, *100*, 6358-6363.
50. Chakravarthy, M.V.; Pan, Z.; Zhu, Y.; Tordjman, K.; Schneider, J.G.; Coleman, T.; Turk, J.; Semenkovich, C.F. "New" hepatic fat activates pparalpha to maintain glucose, lipid, and cholesterol homeostasis. *Cell metabolism* **2005**, *1*, 309-322.
51. Ohashi, K.; Osuga, J.; Tozawa, R.; Kitamine, T.; Yagyu, H.; Sekiya, M.; Tomita, S.; Okazaki, H.; Tamura, Y.; Yahagi, N., *et al.* Early embryonic lethality caused by targeted disruption of the 3-hydroxy-3-methylglutaryl-coa reductase gene. *The Journal of biological chemistry* **2003**, *278*, 42936-42941.
52. Douillard-Guilloux, G.; Raben, N.; Takikita, S.; Ferry, A.; Vignaud, A.; Guillet-Deniau, I.; Favier, M.; Thurberg, B.L.; Roach, P.J.; Caillaud, C., *et al.* Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of pompe disease. *Human molecular genetics* **2010**, *19*, 684-696.
53. Castro, E.; Eeles, R. The role of brca1 and brca2 in prostate cancer. *Asian journal of andrology* **2012**, *14*, 409-414.
54. Dedes, K.J.; Wilkerson, P.M.; Wetterskog, D.; Weigelt, B.; Ashworth, A.; Reis-Filho, J.S. Synthetic lethality of parp inhibition in cancers lacking brca1 and brca2 mutations. *Cell cycle* **2011**, *10*, 1192-1199.
55. Cho, Y.Y.; Kang, M.J.; Sone, H.; Suzuki, T.; Abe, M.; Igarashi, M.; Tokunaga, T.; Ogawa, S.; Takei, Y.A.; Miyazawa, T., *et al.* Abnormal uterus with polycysts, accumulation of uterine prostaglandins, and reduced fertility in mice heterozygous for acyl-coa synthetase 4 deficiency. *Biochemical and biophysical research communications* **2001**, *284*, 993-997.
56. Dubrovsky, A.L.; Taratuto, A.L.; Sevelev, G.; Schultz, M.; Pegoraro, E.; Hoop, R.C.; Hoffman, E.P. Duchenne muscular dystrophy and myotonic dystrophy in the same patient. *American journal of medical genetics* **1995**, *55*, 342-348.
57. Iyer, R.K.; Yoo, P.K.; Kern, R.M.; Rozengurt, N.; Tsoa, R.; O'Brien, W.E.; Yu, H.; Grody, W.W.; Cederbaum, S.D. Mouse model for human arginase deficiency. *Molecular and cellular biology* **2002**, *22*, 4491-4498.

58. Chen, Z.; Karaplis, A.C.; Ackerman, S.L.; Pogribny, I.P.; Melnyk, S.; Lussier-Cacan, S.; Chen, M.F.; Pai, A.; John, S.W.; Smith, R.S., *et al.* Mice deficient in methylenetetrahydrofolate reductase exhibit hyperhomocysteinemia and decreased methylation capacity, with neuropathology and aortic lipid deposition. *Human molecular genetics* **2001**, *10*, 433-443.
59. Greig, K.T.; Antonchuk, J.; Metcalf, D.; Morgan, P.O.; Krebs, D.L.; Zhang, J.G.; Hacking, D.F.; Bode, L.; Robb, L.; Kranz, C., *et al.* Agm1/pgm3-mediated sugar nucleotide synthesis is essential for hematopoiesis and development. *Molecular and cellular biology* **2007**, *27*, 5849-5859.
60. Wang, L.; Magdaleno, S.; Tabas, I.; Jackowski, S. Early embryonic lethality in mice with targeted deletion of the ctp:Phosphocholine cytidyltransferase alpha gene (pcyt1a). *Molecular and cellular biology* **2005**, *25*, 3357-3363.
61. Wu, G.; Aoyama, C.; Young, S.G.; Vance, D.E. Early embryonic lethality caused by disruption of the gene for choline kinase alpha, the first enzyme in phosphatidylcholine biosynthesis. *The Journal of biological chemistry* **2008**, *283*, 1456-1462.